News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. GoodRx Holdings (GDRX) is back in focus after its Q2 2026 earnings report on …
GoodRx Holdings (GDRX) has appointed Justin Fengler as Chief Financial Officer and Treasurer, consolidating financial, strategy, and operations under his existing role as Chief Strategy & Operations Officer. This move aims to align financial decisions with the company's growth initiatives, such as pharma partnerships …
Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q2 CY2026 results beating Wall Street's revenue expectations , but sales fell by 1.3% year on year to $200.4 million. The company's full-year revenue guidance of $797.5 million at the midpoint came in 2.8% above analysts' estimates. Its …
GoodRx (GDRX) CEO & president Wendy Barnes joins Josh Lipton on Market Domination to discuss the company's strategy to expand beyond prescription savings. Highlighting strong growth across the business, with subscription revenue up 39% and direct-to-pharma sales rising 76% year over year. Video Transcript …
GoodRx Holdings (NASDAQ: GDRX) has appointed Justin Fengler as its new Chief Financial Officer and Treasurer, effective August 6, 2026. Fengler, previously the Chief Strategy & Operations Officer, will continue to oversee strategy and operations. Christopher McGinnis will transition from the CFO role on …
GoodRx (GDRX) stock rose 13.8% following its Q2 2026 earnings report, driven by stronger margins and an adjusted EBITDA of US$63.7m, despite a slight revenue decline. The company is seeing increased traction in subscription services and Pharma Direct revenue, validating its margin-focused strategy. However, …
This article provides an earnings forecast for GoodRx Holdings Inc (GDRX), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 15 analysts, the stock has a "Hold" rating, with an average price target of $5.00. The expected revenue for …
GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q2 CY2026 results exceeding the market's revenue expectations , but sales fell by 1.3% year on year to $200.4 million. The company's full-year revenue guidance of $797.5 million at the …
Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-Over-Year Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations SANTA MONICA, Calif., August 05, 2026--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings …
GoodRx Holdings Inc (GDRX) currently has an earnings forecast score of 6.67, placing it 338th out of 485 in the Software & IT Services industry. The average analyst price target for GDRX is $5.00, with forecasts ranging from $3.00 to $7.00. Based on ratings …
This article provides a comprehensive overview of GoodRx Holdings Inc (GDRX), including its stock performance, key financial figures, and analyst ratings. It highlights that GoodRx's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Software & IT …
GoodRx (GDRX): Buy, Sell, or Hold Post Q1 Earnings? GoodRx has had an impressive run over the past six months as its shares have beaten the S&P 500 by 13.1%. The stock now trades at $3.14, marking a 21.5% gain. This was partly thanks …
Wendy Lynn Barnes, a director and executive at GoodRx Holdings, converted 277,288 restricted stock units (RSUs) into Class A common stock on July 15, 2026. To cover tax obligations, 120,456 shares were withheld at $3.01 per share, rather than being sold in open-market transactions. …
GoodRx Holdings, Inc.'s Chief Accounting Officer, Thomas Chan, engaged in equity compensation activity, exercising restricted stock units (RSUs) to acquire 5,792 shares of Class A Common Stock. Concurrently, 2,947 shares were withheld for tax purposes at a price of $3.01 per share. Following these …
This article provides an update on GoodRx Holdings, Inc. with a focus on an insider transaction filing. It notes a Form 3/4/5 filing on July 16, 2026, which can be viewed on SEC.gov. The platform MLQ.ai also offers research, including a report on "The …
This article reports on a Form 4 filing for GoodRx Holdings Inc. dated July 16, 2026, as published by Investing.com. It is a brief announcement indicating the filing of an insider trading report for the company on that specific date. The content is very …
Search by ticker symbol or company name and select a result to open its chart.